Edition:
United States

People: Biogen Inc (BIIB.O)

BIIB.O on Nasdaq

250.80USD
26 May 2017
Change (% chg)

$-2.17 (-0.86%)
Prev Close
$252.97
Open
$252.59
Day's High
$253.62
Day's Low
$250.51
Volume
833,069
Avg. Vol
1,625,502
52-wk High
$333.65
52-wk Low
$223.02

Sherwin, Stephen 

Dr. Stephen A. Sherwin, M.D. is the Independent Director of Biogen Idec Inc., since March 2010. Dr. Sherwin has served as one of our directors since 2010. Dr. Sherwin currently divides his time between advisory work in the life sciences industry and patient care and teaching in his specialty of medical oncology. He is a Clinical Professor of Medicine at the University of California, San Francisco, and a volunteer Attending Physician in Hematology-Oncology at San Francisco General Hospital. Dr. Sherwin also currently serves as a venture partner with Third Rock Ventures, LLC. Dr. Sherwin previously served as the Chairman of Ceregene, Inc., a life sciences company that he co-founded, from 2001 until its acquisition by Sangamo Biosciences, Inc. in 2013. He was also a co-founder and chairman of Abgenix, Inc., an antibody company which was acquired by Amgen Inc. in 2006. From 1990 to October 2009, he served as the Chief Executive Officer of Cell Genesys, Inc., a life sciences company, and was its Chairman from 1994 until the company’s merger with BioSante Pharmaceuticals, Inc. in October 2009. Prior to that, he held various positions at Genentech, Inc., a life sciences company, most recently as Vice President, Clinical Research. Dr. Sherwin is a member of the Boards of Directors of Neurocrine Biosciences, Inc., Rigel Pharmaceuticals, Inc., and Aduro Biotech, Inc., all of which are clinical-stage life sciences companies. During the past five years, Dr. Sherwin also served as a director of BioSante Pharmaceuticals until its merger with ANI Pharmaceuticals, Inc. in September 2013, Vical Inc., and Verastem Inc.

Basic Compensation

Total Annual Compensation, USD 133,000
Restricted Stock Awards, USD 269,420
Long-Term Incentive Plans, USD --
All Other, USD 25,000
Fiscal Year Total, USD 427,420

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Stelios Papadopoulos

627,630

Michel Vounatsos

5,801,050

Paul Clancy

5,385,200

Kenneth Di Pietro

3,989,900

Susan Alexander

4,167,300

Michael Ehlers

5,512,540
As Of  30 Dec 2016